Yesterday, Feb. 24, 2016, 77 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $250.66 to $7,618,160.00.

Highlighted Stocks Traded by Insiders:

Ciena (CIEN) - FREE Research Report

Claflin Bruce L., who is Director at Ciena, sold 800 shares at $20.00 on Feb. 24, 2016. Following this transaction, the Director owned 58,562 shares meaning that the stake was reduced by 1.35% with the 800-share transaction.

The shares most recently traded at $20.56, up $0.56, or 2.72% since the insider transaction. Historical insider transactions for Ciena go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 8,000
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 287,353
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 354,422

The average volume for Ciena has been 3.4 million shares per day over the past 30 days. Ciena has a market cap of $2.7 billion and is part of the technology sector and telecommunications industry. Shares are down 0.14% year-to-date as of the close of trading on Wednesday.

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. The company has a P/E ratio of 198.9. Currently, there are 15 analysts who rate Ciena a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CIEN - FREE

TheStreet Quant Ratings

rates Ciena as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including a decline in the stock price during the past year and generally higher debt management risk. Get the full

Ciena Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Mulligan Seamus, who is Director at Jazz Pharmaceuticals, sold 27,968 shares at $122.71 on Feb. 24, 2016. Following this transaction, the Director owned 1.1 million shares meaning that the stake was reduced by 2.47% with the 27,968-share transaction.

The shares most recently traded at $121.91, down $0.80, or 0.65% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,600
  • 12-Week # shares sold: 7,800
  • 24-Week # shares sold: 46,313

The average volume for Jazz Pharmaceuticals has been 599,500 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $7.5 billion and is part of the health care sector and drugs industry. Shares are down 13.33% year-to-date as of the close of trading on Wednesday.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 23.3. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings

rates Jazz Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, notable return on equity, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Jazz Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Chase (CCF) - FREE Research Report

Gack Lewis P, who is Director at Chase, sold 550 shares at $48.50 on Feb. 24, 2016. Following this transaction, the Director owned 9,136 shares meaning that the stake was reduced by 5.68% with the 550-share transaction.

The shares most recently traded at $45.62, down $2.88, or 6.31% since the insider transaction. Historical insider transactions for Chase go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 700
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 700
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 2,200

The average volume for Chase has been 30,500 shares per day over the past 30 days. Chase has a market cap of $408.0 million and is part of the industrial goods sector and industrial industry. Shares are up 12.2% year-to-date as of the close of trading on Wednesday.

Chase Corporation manufactures and sells protective materials for various applications worldwide. It operates through two segments, Industrial Materials and Construction Materials segments. The stock currently has a dividend yield of 1.47%. The company has a P/E ratio of 15.3. Currently, there are no analysts who rate Chase a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CCF - FREE

TheStreet Quant Ratings

rates Chase as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Chase Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.